Lumos Diagnostics HoldingsLDXHF 31 PB Ratio is 11.43 as of Jun. 25, 2026, which is 628% above its 10-year median of 1.57. GuruFocus rates LDXHF with a GF Score™ of 31/100 and a GF Value™ of $0.02 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 787 Medical Devices & Instruments companies, Lumos Diagnostics Holdings ranks worse than 92.88% on this metric.
The historical rank and industry rank for Lumos Diagnostics Holdings's PB Ratio or its related term are showing as below:
LDXHF'
s PB Ratio Range Over the Past 10 Years
Min: 0.1 Med: 1.57 Max: 24.62
Current: 8
During the past 4 years, Lumos Diagnostics Holdings's highest PB Ratio was 24.62. The lowest was 0.10. And the median was 1.57.
LDXHF's PB Ratio is ranked worse than 92.88% of 787
companies
in the Medical Devices & Instruments industry
Industry Median: 2.04
vs LDXHF: 8.00
During the past 12 months, Lumos Diagnostics Holdings's average Book Value Per Share Growth Rate was -52.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -51.50% per year.
During the past 4 years, the highest 3-Year average Book Value Per Share Growth Rate of Lumos Diagnostics Holdings was -51.50% per year. The lowest was -51.50% per year. And the median was -51.50% per year.
Back to Basics: PB Ratio
Lumos Diagnostics Holdings (OTCPK:LDXHF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Lumos Diagnostics Holdings PB Ratio Related Terms
Lumos Diagnostics Holdings PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Lumos Diagnostics Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lumos Diagnostics Holdings PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Lumos Diagnostics Holdings's PB Ratio distribution charts can be found below:
* The bar in red indicates where Lumos Diagnostics Holdings's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Lumos Diagnostics Holdings (LDXHF) has a PB Ratio of 11.43 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Lumos Diagnostics Holdings and its competitors. This is 628% above median its historical median of 1.57. Over the past decade, Lumos Diagnostics Holdings' PB Ratio has ranged from 0.10 to 24.62. According to the industry distribution chart, Lumos Diagnostics Holdings ranks #731 out of 787 companies in the Medical Devices & Instruments industry, placing it in the top 92.9%.
Is Lumos Diagnostics Holdings' PB Ratio too high?
Lumos Diagnostics Holdings' current PB Ratio of 11.43 is 628% above median its 10-year median of 1.57. Over the past 10 years, this metric has ranged from a low of 0.10 to a high of 24.62. The Medical Devices & Instruments industry median PB Ratio is 2.04. Lumos Diagnostics Holdings' value of 11.43 is 460.3% above this industry median. Based on the distribution chart, Lumos Diagnostics Holdings ranks #731 out of 787 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Lumos Diagnostics Holdings has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lumos Diagnostics Holdings' PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Lumos Diagnostics Holdings ranks #731 out of 787 companies for PB Ratio. This places Lumos Diagnostics Holdings in the lower half of its industry. The industry median PB Ratio is 2.04. Lumos Diagnostics Holdings' value of 11.43 is 460.3% above this benchmark. Historically, Lumos Diagnostics Holdings' own PB Ratio has ranged from 0.10 to 24.62 over the past decade. While the company's 10-year median is 1.57 vs. the industry median of 2.04, Lumos Diagnostics Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.04, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lumos Diagnostics Holdings's current PB Ratio of 11.43 is 460.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Lumos Diagnostics Holdings and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lumos Diagnostics Holdings's current PB Ratio is 11.43, which is 628% above median its own 10-year median of 1.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumos Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lumos Diagnostics Holdings (LDXHF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.08 — trading 300% above its estimated fair value. The current PB Ratio is 11.43, which is 628% above median its 10-year median of 1.57 and 460.3% above the Medical Devices & Instruments industry median of 2.04. Lumos Diagnostics Holdings' overall GF Score™ is 31/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Lumos Diagnostics Holdings (LDXHF), the current PB Ratio is 11.43 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lumos Diagnostics Holdings (LDXHF) Overvalued in 2026?
Based on GuruFocus' analysis, Lumos Diagnostics Holdings stock appears to be overvalued.
The current stock price of $0.08 is trading 300% above its estimated GF Value™ of $0.02.
GuruFocus considers Lumos Diagnostics Holdings to be Significantly Overvalued.
Key valuation signals for LDXHF:
PB Ratio: 11.43 (628% above median its 10-year median of 1.57)
GF Value™: $0.02 vs. price of $0.08 (300% above fair value)
Industry Position: 460.3% above the Medical Devices & Instruments median (#731 of 787)
No single metric tells the full story. See the LDXHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture, and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. The group is dedicated to providing contract research and development services, focusing on the innovation, development, manufacturing, and commercialization of point-of-care diagnostic solutions for both clinical and consumer applications. It generates maximum revenue from commercial services and solutions relating to POC diagnostic tests. The group has one operating segment, which is the provision of point-of-care diagnostics goods and services. The Company operates in two geographical regions, the United States and Australia and the majority of revenue is generated from the United States.
31GF Score
Get the complete analysis for LDXHF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LDXHF has been successfully added to your 
